Precision BioSciences stock (US74019P1084): Q3 2024 earnings report shows EPS loss

Precision BioSciences (DTIL), a clinical-stage gene editing company, announced its third quarter 2024 earnings on November 2024, posting an EPS of $-2.83 versus Zacks consensus estimates, according to Zacks as of November 2024. The results reflect continued investment in its ARCUS nuclease platform for therapies targeting liver diseases and cancer. Investors will watch for pipeline updates in 2026.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Precision BioSciences: core business model

Precision BioSciences develops gene editing therapies using its proprietary ARCUS platform, which enables precise DNA modifications for treating genetic diseases. The technology targets specific genomic sites with smaller, more deliverable nucleases compared to competitors. The company focuses on in vivo editing for liver-directed therapies like primary hyperoxaluria type 1 (PH1) and hepatitis B, according to its investor site as of 2026.

ARCUS has shown preclinical promise in oncology and autoimmune applications. Precision BioSciences advances candidates through partnerships, including with Gilead for hepatitis B and Orum Therapeutics for NK cell therapies. This model balances internal development with milestone-based revenue.

Main revenue and product drivers for Precision BioSciences

Revenue stems from collaboration agreements and potential milestone payments. In Q3 2024, the company reported ongoing R&D expenses tied to clinical trials, contributing to the EPS loss of $-2.83 for the period ending September 2024, per Zacks as of November 2024. Key drivers include PBGENE-HBV advancements and next-gen candidates.

The pipeline features in vivo liver editing programs, with PH1 candidate in Phase 1/2 trials. Partnerships provide non-dilutive funding, critical for US biotech investors tracking cash burn in gene therapy space.

Conclusion

Precision BioSciences continues advancing its ARCUS platform amid Q3 2024 losses, with focus on gene editing milestones. US investors note its Nasdaq listing and exposure to high-growth biotech sectors. Developments in partnerships and trials will shape near-term trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.